¼¼°èÀÇ µÅÁö ¹é½Å ½ÃÀå
Swine Vaccines
»óǰÄÚµå : 1777608
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 398 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ µÅÁö ¹é½Å ½ÃÀåÀº 2030³â±îÁö 21¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 17¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µÅÁö ¹é½Å ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 3.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 21¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÒȰ¼ºÈ­´Â CAGR4.1%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 13¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼öÁ¤/ºÒȰ¼ºÈ­ »ý±Õ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 4¾ï 6,260¸¸ ´Þ·¯, Áß±¹Àº CAGR6.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ µÅÁö ¹é½Å ½ÃÀåÀº 2024³â¿¡ 4¾ï 6,260¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.9%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 4¾ï 2,440¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.4%¿Í 2.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ µÅÁö ¹é½Å ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ö ¹é½ÅÀÌ Çö´ë ¾çµ·Àå °ü¸®ÀÇ Áß½ÉÀÌ µÇ°í Àִ°¡?

¼¼°è ¾çµ· »ê¾÷Àº ½ÅÁ¾ Àü¿°º´°ú ¹ÙÀÌ¿À º¸¾È À§ÇùºÎÅÍ Ç×»ýÁ¦ °¨Ãà ¾Ð·Â Áõ°¡¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »óȲ ¼Ó¿¡¼­ ¹é½ÅÀº ¿¹¹æÀû ¼±Åÿ¡¼­ °¡Ã౺ °Ç°­ Àü·«ÀÇ ±âÃʰ¡ µÇ´Â ¿ä¼Ò·Î ÁøÈ­ÇØ ¿Ô½À´Ï´Ù. ¾ÆÇÁ¸®Ä«µÅÁö¿­º´(ASF), µÅÁö»ý½Ä±âÈ£Èí±âÁõÈıº(PRRS), °íÀüÀû µÅÁö¿­º´(CSF)°ú °°Àº Áúº´ÀÌ ÁÖ¿ä µÅÁö°í±â »ý»ê Áö¿ª Àüü¿¡ Ä¡¸íÀûÀÎ ¼Õ½ÇÀ» ÃÊ·¡ÇÔ¿¡ µû¶ó, »ý»êÀÚµéÀº À§ÇèÀ» ÁÙÀÌ°í »ý»êÀÇ ¿¬¼Ó¼ºÀ» º¸È£Çϱâ À§ÇØ ¹é½Å Á¢Á¾ ÇÁ·ÎÅäÄÝ¿¡ Á¡Á¡ ´õ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù. ¹é½ÅÀº dzÅ亴À» ¾ïÁ¦ÇÏ´Â µ¥ µµ¿òÀÌ µÉ »Ó¸¸ ¾Æ´Ï¶ó ÀÌÂ÷ °¨¿°ÀÇ ¹ß»ý·üÀ» ³·Ãß°í Ç×±ÕÁ¦ÀÇ Àüü »ç¿ë·®À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾çµ·ÀÇ ±Ô¸ð¿Í ¹Ðµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ±Þ¼ÓÇÑ Áúº´ ÀüÆÄÀÇ À§ÇùÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌȯÀ²°ú Æó»çÀ²À» ÃÖ¼ÒÈ­Çϱâ À§ÇØ Á¤±âÀûÀÎ ¿¹¹æÁ¢Á¾ÀÌ ÇʼöÀûÀÔ´Ï´Ù. ±× °á°ú, ¹é½Å Á¢Á¾Àº ´õ ÀÌ»ó ºñ¿ëÀ¸·Î °£ÁÖµÇÁö ¾Ê°í, µ·±ºÀÇ È¸º¹·Â, »ý»ê¼º ¹× Àå±âÀûÀÎ ¼öÀͼºÀ» ³ôÀ̱â À§ÇÑ ÅõÀÚ·Î °£ÁֵǾî Àü ¼¼°èÀûÀ¸·Î µÅÁö °Ç°­ °ü¸®ÀÇ ÇÙ½ÉÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

»õ·Î¿î ¹é½Å ±â¼úÀº µÅÁö Áúº´ ¿¹¹æ¿¡ ¾î¶² º¯È­¸¦ °¡Á®¿À°í Àִ°¡?

±â¼ú Çõ½ÅÀº µÅÁö ¹é½ÅÀÇ °³¹ß ¹× °ø±ÞÀ» À籸¼ºÇÏ¿© ´õ ºü¸£°í, ´õ È¿°úÀûÀ̸ç, ´õ Ÿ°ÙÆÃµÈ ¿¹¹æÁ¢Á¾ Àü·«À» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ DNA ±â¼ú, ¹ÙÀÌ·¯½º º¤ÅÍ Ç÷§Æû, RNA ±â¹Ý ¹é½ÅÀÇ ¹ßÀüÀº ºÎÀÛ¿ëÀ» ÁÙÀ̸鼭 ´õ ³ÐÀº ¿¹¹æ È¿°ú¸¦ Á¦°øÇÏ´Â Â÷¼¼´ë ¼Ö·ç¼ÇÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. °¨¿°µ¿¹°°ú ¹é½Å Á¢Á¾ µ¿¹°À» ±¸ºÐÇÏ´Â ¹é½ÅÀÎ DIVA ¹é½ÅÀº ¹«º´ ÀÎÁõÀ» À¯ÁöÇϸ鼭 ¼­¹ÙÀ̹úÀ» Áö¿øÇϱ⠶§¹®¿¡ ƯÈ÷ CSF¿Í °°ÀÌ ¹«¿ª¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúº´¿¡¼­ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹é½Å Á¢Á¾ ½ºÄÉÁÙÀ» °£¼ÒÈ­Çϰí Á¢Á¾ Áß µ¿¹°ÀÇ ½ºÆ®·¹½º¸¦ ÁÙÀ̱â À§ÇØ ´Ù°¡¹é½Å°ú È¥ÇÕ¹é½ÅÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. Çdz» Åõ¿© ¹× ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â Àü´Þ ½Ã½ºÅÛÀº Á¶Á÷ ¼Õ»ó ¹× ±³Â÷ ¿À¿°ÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ¿© µ¿¹° º¹Áö¿Í ¹ÙÀÌ¿À º¸¾ÈÀ» ¸ðµÎ Çâ»ó½Ãŵ´Ï´Ù. Áø´Ü ¿¬µ¿Çü ¹é½Å Á¢Á¾(DLV) ½Ã½ºÅÛµµ ½Ã¹üÀûÀ¸·Î µµÀÔµÇ¾î ½Ç½Ã°£ Áúº´ Áø´Ü°ú ¹é½Å Á¢Á¾ °áÁ¤À» ÅëÇÕÇÏ¿© Á¢Á¾ ½Ã±â¿Í È¿°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº »ý»êÀÚ°¡ Àüü ¼Ò±º¿¡¼­ ´õ ³ôÀº ¸é¿ª ¼öÁØÀ» ´Þ¼ºÇϰí, ³ëµ¿ ½Ã°£À» ´ÜÃàÇϸç, ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥À» ÁøÈ­ÇÏ´Â Áúº´ ¾Ð·Â¿¡ ¸Â°Ô Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦, ¹«¿ª ¿ªÇÐ, ¹ÙÀÌ¿À º¸¾È Àǹ«´Â ¾î¶² ¿ªÇÒÀ» Çϴ°¡?

µÅÁö ¹é½Å ½ÃÀåÀº ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ±¹Á¦ ¹«¿ª »óȲ, ÁøÈ­ÇÏ´Â ¹ÙÀÌ¿À º¸¾È Àǹ«ÀÇ ¿µÇâÀ» ¸¹ÀÌ ¹Þ½À´Ï´Ù. ¸¹Àº ±¹°¡¿¡¼­ ¹é½ÅÀÇ »ç¿ëÀº USDA, EMA, CFDA µî Á¤ºÎ ´ç±¹¿¡ ÀÇÇØ ¾ö°ÝÇÏ°Ô ±ÔÁ¦µÇ°í ÀÖÀ¸¸ç, ¾ÈÀü¼º, À¯È¿¼º ¹× ±ÔÁ¤ Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ ½ÂÀÎ °æ·Î°¡ ¸¶·ÃµÇ¾î ÀÖ½À´Ï´Ù. ¼¼°è µÅÁö°í±â ±³¿ª, ƯÈ÷ ¾Æ½Ã¾Æ, À¯·´, ºÏ¹Ì, ³²¹Ì °£ ±³¿ªÀÌ Áö¼ÓÀûÀ¸·Î È®´ëµÊ¿¡ µû¶ó Áúº´ °ü¸®´Â ¼öÃâ ÀÚ°ÝÀÇ Çʼö Á¶°ÇÀÌ µÇ°í ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥°ú ¹«º´ »óŸ¦ Áõ¸íÇÒ ¼ö ÀÖ´Â ±¹°¡´Â ½ÃÀå Á¢±Ù°ú ¹«¿ª ÆÄÆ®³Ê¸¦ À¯ÁöÇÏ´Â µ¥ Å« ÀÌÁ¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¤ºÎ´Â ƯÈ÷ ASF³ª ±¸Á¦¿ª(FMD)°ú °°Àº ½Å°í °¡´ÉÇÑ ±¹°æ °£ Áúº´¿¡ ´ëÇÑ ´ë±Ô¸ð ¹é½Å Á¢Á¾ Ä·ÆäÀο¡ ÀÚ±ÝÀ» Áö¿øÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¾÷°è°¡ ÁÖµµÇÏ´Â ÀÎÁõ ¹× ¼Ò¸Å¾÷ü Á¶´Þ ¿ä°ÇÀº µ¿¹° º¹Áö ¹× Áö¼Ó°¡´É¼º¿¡ ´ëÇÑ ³ë·ÂÀÇ ÀÏȯÀ¸·Î »ý»êÀÚµéÀÌ Á¾ÇÕÀûÀÎ ¹é½Å Á¢Á¾ ±â·ÏÀ» À¯ÁöÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À º¸¾ÈÀº ¾çµ·¾÷ÀÇ ÇÙ½É °³³äÀ¸·Î ÀÚ¸® Àâ¾ÒÀ¸¸ç, ƯÈ÷ ÃÖ±Ù ¹ß»ýÇÑ Áúº´À» °í·ÁÇÒ ¶§ ¹é½ÅÀº Á¾ÇÕÀûÀÎ Áúº´ ¿¹¹æ ÇÁ·ÎÅäÄÝÀÇ Ã¹ ¹øÂ° ¹æ¾î¼±À¸·Î °£Áֵǰí ÀÖ½À´Ï´Ù. ±ÔÁ¦, ¹«¿ª ¹× ³óÀå ¼öÁØÀÇ ±â´ëÄ¡°¡ ÀÏÄ¡ÇÔ¿¡ µû¶ó ÃֽŠ¾çµ· »ý»êÀÇ ¹æ¾î ¼ö´ÜÀÌÀÚ Áؼö ¿ä°ÇÀ¸·Î¼­ ¹é½Å µµÀÔÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù.

µÅÁö ¹é½Å ½ÃÀåÀÇ °­·ÂÇÑ ¼ºÀå ¿øµ¿·ÂÀº?

µÅÁö ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº ¿ªÇÐ µ¿Çâ, ±â¼ú ¹ßÀü, »ý»ê ½Ã½ºÅÛ ÁøÈ­, ¼¼°è Á¤Ã¥ Á¶Á¤ µî ´Ù¾çÇÑ ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ÀÌ·ç¾îÁý´Ï´Ù. PRRS, Æó·Å ¸¶ÀÌÄÚÇöóÁ, ASF¿Í °°Àº Àü¿°º´ ¹× ½ÅÈï Áúº´ÀÇ À¯ÇàÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹¹æ ¹é½Å°ú ±ä±Þ ¹é½Å¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. º¸Á¶Á¦, Ç׿ø Ž»ö, ¹é½Å Àü´Þ ºÐ¾ßÀÇ ±â¼ú ¹ßÀüÀº Á¦Ç°ÀÇ °¡¿ë¼º°ú È¿´ÉÀ» È®ÀåÇϰí, »õ·Î¿î ±â¼ú Çõ½Å ºÐ¾ß¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ±ÝÁö, ¼öÃâ ±âÁØ, ¼ÒºñÀÚ ÀǽĿ¡ ÈûÀÔ¾î Ç×»ýÁ¦¿¡¼­ ¹é½ÅÀ¸·Î ÀüȯÇϸ鼭 ÁÖ¿ä Áúº´ °ü¸® Àü·«À¸·Î¼­ ¹é½ÅÀÇ Á߿伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. »ý»ê ¼öÁØ¿¡¼­ ¾çµ·ÀÇ °­È­¿Í ´ë±Ô¸ð °æ¿µÀÇ ÅëÇÕÀ¸·Î °¡Ã౺ °Ç°­ °ü¸®ÀÇ °æÁ¦Àû °¡Ä¡°¡ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, ¹é½ÅÀº À§Çè °¨¼ÒÀÇ ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í º´ÇàÇÏ¿© ¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä«, ¾ÆÇÁ¸®Ä«¿¡¼­´Â ¹Î°ü ÆÄÆ®³Ê¿Í Á¤ºÎ°¡ ÀÚ±ÝÀ» Áö¿øÇÏ´Â ¿¹¹æÁ¢Á¾ ÀÌ´Ï¼ÅÆ¼ºê°¡ »ó¾÷ ¹× ¼Ò±Ô¸ð ³ó°¡ ¸ðµÎ¿¡ ¹é½ÅÀ» µµÀÔÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϰí ÀÖ½À´Ï´Ù. ÄݵåüÀÎ ¹°·ùÀÇ °³¼±, ¼öÀÇÇÐ Á¤º¸ÇÐÀÇ ºÎ»ó, Á¤¹Ð Ãà»ê Ç÷§Æû¿¡ ¹é½Å Á¢Á¾ÀÇ ÅëÇÕÀº Á¢±Ù¼º°ú ¿µÇâ·ÂÀ» ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀεéÀÌ °áÇÕµÇ¾î µÅÁö ¹é½Å ½ÃÀåÀº Àü ¼¼°èÀûÀ¸·Î Áö¼Ó °¡´ÉÇϰí È®Àå °¡´ÉÇÏ¸ç »ý¹°ÇÐÀûÀ¸·Î ¾ÈÀüÇÑ µÅÁö°í±â »ý»êÀÇ Áß¿äÇÑ ÃàÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ºÒȰ¼ºÈ­, ¾àµ¶È­, ±âŸ), Áúº´ À¯Çü(µÅÁö ÀÎÇ÷翣ÀÚ, µ·¿­, µÅÁö ÆÄº¸¹ÙÀÌ·¯½º, µÅÁö ¼­ÄÚÀ§¸£½º 2Çü, M.Hyo, ¾ÆÅ©Ä¡³ë¹ÙÄ¡¸£½º Æó·Å, PRRS, ±¸Á¦¿ª, ±¤°ßº´, PEDV, ±âŸ), Åõ¿© °æ·Î(ÁÖ»çÁ¦, °æºñÁ¦, °æ±¸Á¦)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõ µÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Swine Vaccines Market to Reach US$2.1 Billion by 2030

The global market for Swine Vaccines estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Modified / Attenuated Live segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$462.6 Million While China is Forecast to Grow at 6.9% CAGR

The Swine Vaccines market in the U.S. is estimated at US$462.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$424.4 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Swine Vaccines Market - Key Trends & Drivers Summarized

Why Are Vaccines Becoming Central to Modern Swine Herd Management?

The global swine industry is confronting mounting challenges ranging from emerging infectious diseases and biosecurity threats to growing pressure for antibiotic reduction. In this context, vaccines have evolved from a preventive option to a foundational component of herd health strategies. With disease outbreaks like African Swine Fever (ASF), Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever (CSF) causing devastating losses across major pork-producing regions, producers are increasingly leaning on vaccination protocols to mitigate risks and protect production continuity. Vaccines not only help control endemic diseases but also reduce the incidence of secondary infections, lowering the overall use of antimicrobials-a key goal in the global fight against antimicrobial resistance (AMR). Moreover, as pig farming scales up in intensity and density, the threat of rapid disease transmission grows, making routine immunization essential to minimize morbidity and mortality. As a result, vaccination is no longer seen as a cost but rather an investment in herd resilience, productivity, and long-term profitability, securing its place at the core of swine health management worldwide.

How Are New Vaccine Technologies Transforming Swine Disease Prevention?

Technological innovation is reshaping the development and delivery of swine vaccines, enabling faster, more effective, and more targeted immunization strategies. Advances in recombinant DNA technologies, viral vector platforms, and RNA-based vaccines are paving the way for next-generation solutions that offer broader protection with fewer side effects. Marker (DIVA) vaccines-those that differentiate infected from vaccinated animals-are gaining prominence, particularly for diseases with trade implications like CSF, as they support surveillance while maintaining disease-free certifications. Additionally, multivalent and combination vaccines are being developed to simplify vaccination schedules and reduce animal stress during administration. Intradermal and needle-free delivery systems are improving both animal welfare and biosecurity by minimizing tissue damage and cross-contamination risks. Diagnostic-linked vaccination (DLV) systems are also being piloted, integrating real-time disease diagnostics with vaccination decisions to improve timing and efficacy. These innovations are helping producers achieve higher immunity levels across herds, reduce labor time, and tailor vaccination programs to evolving disease pressures-marking a new era in data-driven, precision veterinary medicine.

What Role Do Regulations, Trade Dynamics, and Biosecurity Mandates Play?

The swine vaccines market is deeply influenced by regulatory frameworks, international trade conditions, and evolving biosecurity mandates. In many countries, vaccine use is closely regulated by government authorities such as the USDA, EMA, or CFDA, with strict approval pathways to ensure safety, efficacy, and compliance. As global pork trade continues to grow, especially between Asia, Europe, and the Americas, disease control becomes a prerequisite for export eligibility. Countries that can demonstrate effective vaccination programs and disease-free status have a significant advantage in maintaining market access and trade partnerships. This has pushed governments to fund mass vaccination campaigns, particularly for notifiable and transboundary diseases like ASF and Foot-and-Mouth Disease (FMD). Additionally, industry-driven certifications and retailer sourcing requirements are encouraging producers to maintain comprehensive vaccination records as part of animal welfare and sustainability commitments. Biosecurity has become a central tenet in swine farming, especially in light of recent outbreaks, and vaccines are now viewed as the first line of defense within integrated disease prevention protocols. The alignment of regulatory, trade, and farm-level expectations is reinforcing vaccine adoption as both a protective measure and a compliance requirement in modern swine production.

What’s Driving the Strong Growth in the Swine Vaccines Market?

The growth in the swine vaccines market is driven by a confluence of factors that span epidemiological trends, technological advancement, production system evolution, and global policy alignment. The rising prevalence of infectious and emerging diseases-such as PRRS, Mycoplasma hyopneumoniae, and ASF-is creating sustained demand for both prophylactic and emergency-use vaccines. Technological progress in adjuvant formulations, antigen discovery, and vaccine delivery is broadening product availability and effectiveness, opening up new segments for innovation. The global shift away from antibiotics-driven by regulatory bans, export standards, and consumer awareness-is amplifying the importance of vaccines as a primary disease control strategy. At the production level, intensification of swine farming and the consolidation of large-scale operations are increasing the economic value of herd health management, with vaccines playing a central role in risk mitigation. In parallel, public-private partnerships and government-funded immunization initiatives in Asia, Latin America, and Africa are supporting vaccine deployment in both commercial and smallholder systems. Improved cold chain logistics, the rise of veterinary health informatics, and the integration of vaccination into precision livestock farming platforms are further enhancing accessibility and impact. Together, these drivers are propelling the swine vaccines market forward-solidifying its position as a critical pillar of sustainable, scalable, and biosecure pork production worldwide.

SCOPE OF STUDY:

The report analyzes the Swine Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Inactivated, Modified / Attenuated Live, Others); Disease Type (Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others); Administration Route (Injectables, Intranasal, Oral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â